盤龍藥業(002864.SZ):獲“2021年度最具影響力上市醫藥企業”榮譽稱號
格隆匯7月26日丨盤龍藥業(002864.SZ)公佈,2021年7月22日,由青島市人民政府與中國醫藥物資協會共同主辦、青島市民營經濟發展局和城陽區人民政府共同承辦的“首屆中國醫藥財富大會”在青島國際會議中心舉行。公司在此次會議中獲“2021年度最具影響力上市醫藥企業”榮譽稱號。
公司榮獲“2021年度最具影響力上市醫藥企業獎”是廣大投資者和資本市場對公司高質量發展態勢的認可。公司將繼續堅持“一體兩翼”發展戰略,積極推進盤龍品牌影響力,堅持科技創新,發揮上市公司優勢,加快資產併購步伐,實現公司外延式跨越發展。
公司被評為“2021年度最具影響力上市醫藥企業”,會對公司未來發展產生積極作用,但不會對公司當期經營業績產生重大影響,敬請廣大投資者注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.